Additional Coverage:
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr. (pbs.org)
WASHINGTON – As the Food and Drug Administration prepares to revisit the safety and effectiveness of several popular peptide drugs next month, the makeup of the advisory panel has sparked fresh controversy. The upcoming FDA meeting will feature a new roster of experts, many of whom have direct financial ties to the peptide industry-a marked shift from previous panels dominated by academic researchers.
Peptides, marketed for their supposed benefits in muscle building, injury recovery, and anti-aging, have gained traction among athletes, influencers, and wellness clinics despite limited scientific evidence supporting these claims. The FDA has long expressed concerns over the safety of some injectable peptides like BPC-157 and TB-500, which remain largely unstudied in humans and are banned substances in competitive sports.
Historically, FDA panels reviewing these substances have consisted of independent experts from prestigious institutions such as Duke, Harvard, and Johns Hopkins. These panels often concluded that the risks of offering such peptides to patients outweighed any potential benefits, leading to negative recommendations on their widespread use.
The upcoming two-day meeting, however, introduces a panel comprising multiple practitioners and business owners actively involved in prescribing, compounding, or promoting peptide therapies. For example, Dr.
Haleem Mohammed operates clinics under the Gameday Men’s Health brand in Florida, offering peptide injections alongside other unapproved treatments. Another member, Dr.
Gabriel Alizaidy, charges for consultations on peptide use and boasts a significant social media following where he promotes various peptide products. Additionally, Tennessee state Senator Bobby Harshbarger, a pharmacist with ties to a family pharmacy that markets compounded medications including peptides, will also serve on the panel.
This shift aligns with Health and Human Services Secretary Robert F. Kennedy Jr.’s broader efforts to reshape health policy under the banner of the “Make America Healthy Again” movement-a campaign supported by some peptide proponents but met with skepticism by many pharmaceutical experts who classify these products as unapproved drugs.
The FDA maintains strict transparency and disclosure rules for advisory panels, requiring members to reveal any financial interests that could present conflicts. Yet, Kennedy and his allies have frequently criticized federal expert panels as compromised by conflicts of interest, despite official data to the contrary. Notably, Kennedy replaced the CDC’s vaccine advisory panel last year with a group including members critical of vaccines, a move later challenged by a federal judge.
Kennedy himself has expressed enthusiasm for peptides, describing their use in his personal recovery from injuries. Meanwhile, former FDA Commissioner Marty Makary, who resigned in May, also voiced concerns about the efficiency and potential conflicts within FDA panels, leading to a reduction in formal meetings during his tenure.
As the July review approaches, the composition of the new FDA panel raises questions about the future regulatory stance on peptides, balancing public safety concerns with the interests of a growing wellness industry.
- End –